196 related articles for article (PubMed ID: 32511880)
21. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Brown JR
Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
25. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
[TBL] [Abstract][Full Text] [Related]
26. FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
de Claro RA; McGinn KM; Verdun N; Lee SL; Chiu HJ; Saber H; Brower ME; Chang CJ; Pfuma E; Habtemariam B; Bullock J; Wang Y; Nie L; Chen XH; Lu DR; Al-Hakim A; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Aug; 21(16):3586-90. PubMed ID: 26275952
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Dreger P; Michallet M; Bosman P; Dietrich S; Sobh M; Boumendil A; Nagler A; Scheid C; Cornelissen J; Niederwieser D; Müller L; Vandenberghe E; Scortechini I; Schoemans H; Andersen NS; Finke J; Russo D; Ljungman P; Passweg J; van Gelder M; Durakovic N; Labussiere-Wallet H; Berg T; Wulf G; Bethge W; Bunjes D; Stilgenbauer S; Canepari ME; Schaap M; Fox CP; Kröger N; Montoto S; Schetelig J
Bone Marrow Transplant; 2019 Jan; 54(1):44-52. PubMed ID: 29728701
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib in CLL/SLL: From bench to bedside (Review).
Zi F; Yu L; Shi Q; Tang A; Cheng J
Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
[TBL] [Abstract][Full Text] [Related]
29. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
[TBL] [Abstract][Full Text] [Related]
31. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Maruyama D; Omi A; Nomura F; Touma T; Noguchi Y; Takebe K; Izutsu K
Int J Hematol; 2024 Feb; 119(2):146-155. PubMed ID: 38195971
[TBL] [Abstract][Full Text] [Related]
33. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Egyed M; Lueff S; Borbely J; Illes A
Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
[TBL] [Abstract][Full Text] [Related]
34. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
35. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
Muñoz J; Sarosiek S; Castillo JJ
Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
[TBL] [Abstract][Full Text] [Related]
36. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Zhou Y; Lu H; Yang M; Xu C
Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
38. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R; Ostrowski SR; Nasserinejad K; Kersting S; Dobber JA; Mattson M; Tran HTT; Levin MD; Mous R; Kater AP; Niemann CU
Leuk Lymphoma; 2020 Dec; 61(14):3422-3431. PubMed ID: 32865439
[TBL] [Abstract][Full Text] [Related]
39. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
40. The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.
Karel MFA; Tullemans BME; D'Italia G; Lemmens TP; Claushuis TAM; Kuijpers MJE; Cosemans JMEM
Thromb Res; 2022 Apr; 212():72-80. PubMed ID: 35247800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
